Daptomycin intravenous - Merck & Co.
Alternative Names: Cubicin; Deptomycin; LY-146032; MK-3009Latest Information Update: 05 Nov 2023
At a glance
- Originator Eli Lilly and Company
- Developer AstraZeneca; Banyu; Cubist Pharmaceuticals; Merck & Co; Novartis; Sunovion Pharmaceuticals Canada
- Class Antibacterials; Cyclic peptides; Lipopeptides; Peptide antibiotics
- Mechanism of Action Cell wall inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Bacteraemia; Bacterial endocarditis; Gram-positive infections; Methicillin-resistant Staphylococcus aureus infections; Skin and soft tissue infections; Staphylococcal infections
- Phase III Osteomyelitis
- Discontinued Community-acquired pneumonia; Urinary tract infections
Most Recent Events
- 14 Sep 2022 Launched for Bacteraemia (In adolescents, In children, In infants) in Japan (IV) before September 2022
- 14 Sep 2022 Launched for Methicillin-resistant Staphylococcus aureus infections (In adolescents, In children, In infants) in Japan (IV) before September 2022
- 14 Sep 2022 Launched for Skin and soft tissue infections (In adolescents, In children, In infants, Complicated) in Japan (IV) before September 2022